Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

11.31 +0.13 (+1.16%)
Streaming Delayed Price Updated: 9:56 AM EDT, Sep 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 130,748
Open 11.04
Bid (Size) 11.29 (300)
Ask (Size) 11.33 (400)
Prev. Close 11.18
Today's Range 11.04 - 11.31
52wk Range 4.750 - 11.94
Shares Outstanding 133,976,538
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript ↗
HDV combination therapy achieved 88% viral clearance, advancing toward Phase 3 readouts. 
Via The Motley Fool
Topics Earnings

Performance

YTD
+90.4%
+90.4%
1 Month
+27.2%
+27.2%
3 Month
+32.9%
+32.9%
6 Month
+14.5%
+14.5%
1 Year
+117.9%
+117.9%

More News

Read More
News headline image
Vir Biotechnology Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
Vir Biotechnology (NASDAQ:VIR) Jumps 10% on Q2 Beat and Astellas Collaboration ↗
Via Chartmill
7 Bull Flag Setups Found With the ChartMill Stock Screener ↗
Via Chartmill
VIR Biotechnology Inc (NASDAQ:VIR) Emerges as a High-Growth Momentum Pick ↗
Via Chartmill
News headline image
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces Chief Financial Officer Transition
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally ↗
Via The Motley Fool
News headline image
Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Energy Vault Stock Has Surged 500%. One Major Holder Just Sold 3 Million Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares ↗
Via The Motley Fool
News headline image
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies
From World Street Intelligence
Via GlobeNewswire
News headline image
Vir Biotechnology's Chairman of the Board Sold 22,000 Company Shares. Here's What That Means for Investors. ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vir (VIR) Q1 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference
From Vir Biotechnology
Via Business Wire
News headline image
Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology (VIR) CEO Sells 73,000 Shares for $664,000 ↗
Via The Motley Fool
Topics Regulatory Compliance
Unusual volume stocks are being observed in Monday's session. ↗
Via Chartmill

Frequently Asked Questions

Is Vir Biotechnology, Inc. - Common Stock publicly traded?
Yes, Vir Biotechnology, Inc. - Common Stock is publicly traded.
What exchange does Vir Biotechnology, Inc. - Common Stock trade on?
Vir Biotechnology, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vir Biotechnology, Inc. - Common Stock?
The ticker symbol for Vir Biotechnology, Inc. - Common Stock is VIR on the Nasdaq Stock Market
What is the current price of Vir Biotechnology, Inc. - Common Stock?
The current price of Vir Biotechnology, Inc. - Common Stock is 11.31
When was Vir Biotechnology, Inc. - Common Stock last traded?
The last trade of Vir Biotechnology, Inc. - Common Stock was at 09/09/26 09:56 AM ET
What is the market capitalization of Vir Biotechnology, Inc. - Common Stock?
The market capitalization of Vir Biotechnology, Inc. - Common Stock is 1.52B
How many shares of Vir Biotechnology, Inc. - Common Stock are outstanding?
Vir Biotechnology, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.